An increasingly favourable environment allows TAKARA BIO to improve to Neutral
The independent financial analyst theScreener just upgraded the general evaluation of TAKARA BIO (JP), a company active in the Biotechnology industry. As regards its fundamental valuation, the title confirms its rating of 2 out of 4 stars while its market behaviour remains as moderately risky. theScreener believes, however, that a more enabling environment allows the title to increase its general evaluation to Neutral. As of the analysis date February 25, 2022, the closing price was JPY 2,373.00 and its expected value was estimated at JPY 2,415.06.Takara Bio is a bio-technological company. Along with its subsidiaries, Co. operates in three business segments: bioindustry, gene therapy, and agribio. The Bioindustry segment provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The Gene Therapy segment develops and commercializes gene therapies for cancer and AIDS. The AgriBio segment discovers the functionality of traditional Japanese food ingredients, and develops and produces functional foods that utilize these materials. As of Mar 31 2017, Co. has 11 consolidated subsidiaries.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.